Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
Meeting Abstract
Wasan, H. S.; Harding, J. J.; Fan, J.; Oh, D-Y.; Choi, H. J.; Kim, J. W.; Chang, H-M.; Bao, L.; Sun, H.; Macarulla, T.; Xie, F.; Metges, J-P.; Ying, J.; Bridgewater, J. A.; Tejani, M.; Chen, E. Y.; Ducreux, M. P.; Ma, J.; Garfin, P.; Pant, S.